A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.

Freya Biosciences is moving a microbial immunotherapy for IVF implantation failure into mid-stage trials after promising results in healthy volunteers. The Phase 2 study is

The FDA is taking the first step toward potentially backing popular peptides, convening advisors to discuss whether a handful of products should be given the

The XBI is up 30% in six months, beating the S&P 500 by 24 percentage points — and the gap only widened in April.

In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.